A clinical trial named NCT01873833 investigated the combination of TZM with metronomic drugs (CAPE + CTX + Lapatinib) in patients with HER2+ metastatic BC who had previously received TZM administered in either the metastatic or adjuvant setting. Here, ERBB2 is linked to breast cancer.